CTIS2023-509167-24-00RecruitingPhase 1
BYLieve: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients withPIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments. - CBYL719X2402
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- ovartis Pharma AG
- Enrollment
- 3
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •Patient is an adult male or female = 18 years old, Patient has adequate bone marrow function, Patient has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory. It is recommended to provide a tumor sample collected after the most recent progression or recurrence, Advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy, Patient has been confirmed as PIK3CA mutant as determined by a certified designated laboratory, Patient has histologically and/or cytologically confirmed ER+ and/ or PgR+ BC, Patient has confirmed, HER2-negative aBC. HER2-negative defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+, Patients must be diagnosed with aBC, with documented evidence of tumor progression on or after prior treatments. No more than one prior regimen of chemotherapy for the treatment of metastatic disease is permitted. The maximum number of prior therapies for aBC or mBC is limited to two (maintenance therapies, where applicable, must be regarded as part of the main therapy). Patients must have recovered to grade 1 or better from any adverse events (except alopecia) related to previous therapy prior to study entry, Patient has either measurable disease, i.e. at least one measurable lesion as per RECIST v1.1 criteria or if no measurable disease is present than at least one predominantly lytic bone lesion must be present, Patient has ECOG performance status of = 2
Exclusion Criteria
- •Patient has received prior treatment with any PI3K inhibitors, Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II (based on FG and HbA1c in inclusion criterion 11), Patient has a concurrent malignancy or malignancy within 3 years of study screening period, with the exception of adequately treated basal or squamous cell carcinoma, nonmelanoma skin cancer or curatively resected cervical cancer, Patient has received radiotherapy = 4 weeks or limited field radiation for palliation = 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia), Patients receiving systemic corticosteroids = 2 weeks prior to treatment with alpelisib, History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis, Patient has impaired GI function or GI disease that may affect the absorption of study drugs, Patient has documented pneumonitis, Patients being concurrently treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme Cytochrome P (CYP)3A within the last 5 days prior to study entry
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2- negative aBC, with PIK3CA mutations, whose disease has progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-GBovartis Pharma AG340
Active, not recruiting
Phase 1
Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2- negative aBC, with PIK3CA mutations, whose disease has progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004586-67-DKovartis Pharma AG340
Active, not recruiting
Phase 1
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-BEovartis Pharma AG340
Active, not recruiting
Phase 1
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatmentsHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-NLovartis Pharma AG340
Active, not recruiting
Phase 1
Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2- negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or fulvestrantHormone receptor positive, HER2-negative advanced breast cancerMedDRA version: 21.1Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-004586-67-ITOVARTIS PHARMA AG160